Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan receives approvable letter for Restasis

Aug. 25, 1999

Ciba Vision and QLT PhotoTherapeutics seek approval for Visudyne in U.S., Switzerland

Aug. 19, 1999

InSite Vision licenses AquaSite to SSP in Japan

Aug. 18, 1999

Visudyne filed for marketing approval with EMEA

Aug. 11, 1999

Anecortave acetate: a novel angiostatic steroid for the treatment of ocular neovascular diseases

Aug. 4, 1999

Beta-blocker proxodolol, a safe and effective treatment for glaucoma

Aug. 4, 1999

Travoprost is safe and effective in treating elevated IOP in glaucoma patients

Aug. 3, 1999

Allergan profiles its Ocular Hypotensive Lipids at SOE 1999

Aug. 3, 1999

Alcon describes therapeutic potential of ocular antiinflammatory agents

Aug. 3, 1999

Acadia licenses novel leads for glaucoma therapy to Allergan

July 30, 1999

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...